Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3108)
Drug Name
5-FP
Synonyms 5-Fluoro-2(1H)-pyrimidinone
Indication Solid tumour/cancer [ICD11: 2A00-2F9Z] Phase 1 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 114.08 Topological Polar Surface Area 41.5
Heavy Atom Count 8 Rotatable Bond Count 0
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 2
Cross-matching ID
PubChem CID
101498
ChEBI ID
CHEBI:125539
CAS Number
2022-78-8
TTD Drug ID
D02ONT
Formula
C4H3FN2O
Canonical SMILES
C1=C(C=NC(=O)N1)F
InChI
InChI=1S/C4H3FN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)
InChIKey
HPABFFGQPLJKBP-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Fluorouracil DM000190
3385
Unclear - Unclear 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR009800 5-FP 5-Fluoruracil (5-FU) Unclear - Unclear AOX1 [2]
References
1 Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem. 1991 Nov;34(11):3280-4.
2 Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU)

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.